Melanotan 2: What the Research Says

What Melanotan 2 Is

Melanotan II (MT-2) is a synthetic cyclic analogue of α-melanocyte-stimulating hormone (α-MSH). It was developed in the 1980s at the University of Arizona by the research groups of Victor Hruby and Mac Hadley, within a programme searching for a pharmacological route to pigmentation without ultraviolet exposure. Cyclisation through a lactam bridge gives the molecule considerably greater metabolic stability and potency than native α-MSH.

Unlike the natural hormone, MT-2 is a non-selective agonist: it activates the melanocortin receptors MC1R, MC3R, MC4R and MC5R. MC1R in melanocytes governs the switch from pheomelanin to eumelanin, which is the tanning effect. MC3R and MC4R, however, are central receptors involved in appetite, energy balance and sexual behaviour, and MC5R in exocrine function. That lack of receptor selectivity is precisely why the observed effects are never confined to the skin.

Key Research Findings

1. Early phase I observations in humans. Dorr and colleagues (Life Sciences, 1996) reported one of the first controlled administrations of MT-2 in a small group of healthy volunteers, with objectively measurable skin darkening. The sample was very small, and the adverse events noted — nausea, flushing and spontaneous erections — follow directly from activation of the central melanocortin receptors.

2. Photoprotection: what has actually been shown. The idea that induced eumelanin protects against UV damage is biologically reasonable but quantitatively modest; pigmentation alone corresponds to a low protection factor and does not substitute for photoprotection. The only melanocortin analogue with regulatory approval is afamelanotide — a different, linear molecule — authorised by the EMA in 2014 for erythropoietic protoporphyria, a rare condition involving severe phototoxicity. Melanotan II holds no such approval anywhere in the world.

3. Dermatological risk signals. The literature contains published cases of melanoma diagnosed in MT-2 users, along with reports of rapid change in the size, colour and number of naevi; PubMed-indexed reports from 2013–2014 describe exactly this association. Causation is not established — these are case reports, not cohort studies — but the clinically important issue is distinct: induced pigment change makes early dermoscopic recognition of melanoma harder.

4. Systemic adverse events in the case literature. Individual cases of ischaemic priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy syndrome (PRES) have been published in association with MT-2 use. Again these are isolated reports, but taken together they sketch a profile that cannot fairly be called benign.

5. Grey-market material quality. Analytical work, including that of Breindahl and colleagues, examined vials purchased online and found actual peptide content markedly different from the label — in that analysis roughly 4.3 to 8.8 mg against a declared 10 mg — plus synthesis by-products. This is an independent risk factor that has nothing to do with the pharmacology of the molecule. Every batch we supply is accompanied by analysis in the lab testing section.

Safety Profile in the Research

Commonly reported observations include nausea (especially early on), facial flushing, lethargy, darkening of existing naevi and freckles, appetite suppression and, in men, spontaneous erections. The rarer but serious reports are listed above. The regulatory picture is unambiguous: MT-2 is not approved for human use in any jurisdiction. The UK MHRA issued a public warning as early as 2009, classifying it as an unlicensed medicine, and the US FDA has issued warning letters to distributors. Selling it for human use in the EU and the UK is illegal.

Open Questions

There are no long-term prospective data addressing the central question — whether chronic non-selective melanocortin agonism increases the risk of melanocytic dysplasia, or whether the induced pigmentation is on balance protective. Data on cardiovascular regulation under prolonged exposure, and on interaction with other receptor systems, are likewise absent. For context on the more selective melanocortin agonists, see our summary of PT-141 (bremelanotide), and for a peptide with an entirely different mechanism in skin, GHK-Cu. The research material is Melanotan II (MT-2) 10 mg, part of our peptides catalogue.

Specification

Disclaimer: This article is a summary of published scientific literature, provided for research and educational purposes only. PeptaMED supplies all materials strictly for laboratory research use only. They are not medicinal products, food supplements or cosmetics, and they are not intended for human or veterinary consumption, nor for the diagnosis, treatment or prevention of any disease. No human dosing information is given here and no use is recommended. Consult a qualified healthcare professional for any health-related question.

Products mentioned in this article

Melanotan II | 10mg | Dosing Pen€56,00View product →